Biogen and UCB said Tuesday morning that data from a Phase 3 study for the lupus program dapirolizumab pegol were strong ...

A software startup has sued Epic on antitrust grounds, arguing that the electronic health records giant has orchestrated a ...

UCB’s Bimzelx scored three more FDA approvals on Monday, making it the first and only IL-17A and IL-17F inhibitor approved in ...

As the federal government is threatening Johnson & Johnson with fines related to its unilateral alterations to the 340B drug ...

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

A Johnson & Johnson subsidiary filed for bankruptcy in its third attempt to settle a vast majority of cases alleging its talc ...

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...

Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...

Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...

For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...